NordMedica A/S has been acquired by Eurocept B.V.
Maart 2013 — The Dutch pharmaceutical company Eurocept B.V. has acquired 100% of the share capital in the Danish specialty pharmaceutical company NordMedica A/S for an undisclosed consideration.
NordMedica A/S was founded in 2003 as a privately held specialty pharmaceutical company focused on the commercialization and marketing of niche pharmaceutical products. The company holds the rights to an oncology product under the brand names Amekrin®, Amsidine® and Amsidyl® in more than 25 countries. The product is based on a chemotherapy drug for the treatment of Acute Myeloid Leukemia (AML) and Acute Lymphatic Leukemia (ALL). All other assets and liabilities together with all employees were transferred to NordMedica International before the transaction.
Eurocept is a rapidly growing company active in the pharmaceutical and homecare market in the Benelux countries. Eurocept offers products and services that answer to pharmaceutical, technological and nursing needs in medical care as well as a unique combination of medical technology and distribution in the therapeutic areas of anesthesia, oncology, pediatrics, psychiatry, immunology, ADHD and urology.
Onze rol in de transactie
Oaklins' team in Denmark acted as financial and strategic advisor to the seller in this transaction.
Neem contact op met het dealteam
Gerelateerde deals
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Lees verderMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Lees verderQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Lees verder